Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data

2014 ◽  
Vol 50 (4) ◽  
pp. 831-839 ◽  
Author(s):  
Charlotte Le Cornet ◽  
Joannie Lortet-Tieulent ◽  
David Forman ◽  
Rémi Béranger ◽  
Aude Flechon ◽  
...  
Author(s):  
Gorica D. Maric ◽  
Tatjana D. Pekmezovic ◽  
Sarlota T. Mesaros ◽  
Olivera S. Tamas ◽  
Jovana B. Ivanovic ◽  
...  

2018 ◽  
Vol 66 (1) ◽  
pp. e27428 ◽  
Author(s):  
Serena S. Bidwell ◽  
Catherine C. Peterson ◽  
Kathryn Demanelis ◽  
Katie R. Zarins ◽  
Rafael Meza ◽  
...  

2013 ◽  
Vol 14 (9) ◽  
pp. 5367-5370 ◽  
Author(s):  
Alireza Mosavi-Jarrahi ◽  
Toraj Ahmadi-Jouibari ◽  
Farid Najafi ◽  
Yadollah Mehrabi ◽  
Abbas Aghaei

2019 ◽  
Author(s):  
Ines Mesa-Eguiagaray ◽  
Sarah H Wild ◽  
Philip S. Rosenberg ◽  
Sheila M Bird ◽  
David H Brewster ◽  
...  

AbstractBackgroundStrategies for breast cancer prevention are informed by assessing whether incidence differs by tumour biology. We describe temporal trends of breast cancer incidence by molecular subtypes in Scotland.MethodsPopulation-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age- period- cohort models were used to assess whether significant differences were observed in incidence trends by ER status.ResultsER positive tumour incidence steadily increased particularly for women of screening age 50 to 69 years from 1997 till around 2011 (1.6%/year, 95%CI: 1.2 to 2.1). ER negative incidence decreased among all ages at a consistent rate of −0.7%/year (95%CI: −1.5, 0) from around 2000-2016. Compared to the 1941-1959 central birth cohort, women born 1912-1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born 1960- 1986 had higher IRR for ER- tumours.ConclusionsWe show evidence of aetiologic heterogeneity of breast cancer. Future incidence and survival reporting should be monitored by molecular subtypes.


2015 ◽  
Vol 39 (4) ◽  
pp. 425 ◽  
Author(s):  
David Roder ◽  
Nicola Creighton ◽  
Deborah Baker ◽  
Richard Walton ◽  
Sanchia Aranda ◽  
...  

Registries have key roles in cancer incidence, mortality and survival monitoring and in showing disparities across the population. Incidence monitoring began in New South Wales in 1972 and other jurisdictions soon followed. Registry data are used to evaluate outcomes of preventive, screening, treatment and support services. They have shown decreases in cancer incidence following interventions and have been used for workforce and other infrastructure planning. Crude markers of optimal radiotherapy and chemotherapy exist and registry data are used to show shortfalls against these markers. The data are also used to investigate cancer clusters and environmental concerns. Survival data are used to assess service performance and interval cancer data are used in screening accreditation. Registries enable determination of risk of multiple primary cancers. Clinical quality registries are used for clinical quality improvement. Population-based cancer registries and linked administrative data complement clinical registries by providing high-level system-wide data. The USA Commission on Cancer has long used registries for quality assurance and service accreditation. Increasingly population-based registry data in Australia are linked with administrative data on service delivery to assess system performance. Addition of tumour stage and other prognostic indicators is important for these analyses and is facilitated by the roll-out of structured pathology reporting. Data linkage with administrative data, following checks on the quality of these data, enables assessment of patterns of care and other performance indicators for health-system monitoring. Australian cancer registries have evolved and increasingly are contributing to broader information networks for health system management.


Author(s):  
Amr S Soliman ◽  
Saad Alshahrani MD PhD ◽  
Robert M Chamberlain PhD ◽  
Ahmed Hablas MD ◽  
Steven Remmenga MD ◽  
...  

Background: Uterine cancer is one of the common women’s cancers worldwide. There are significant variations in uterine cancer incidence rates globally and the incidence in Egypt is one of the lowest. Several studies have shown that hysterectomy might be a factor in underestimating the observed incidence of uterine cancer. However, no studies have been conducted in Egypt to examine this observation. Methods: Pathologic reports of all 1040 hysterectomy specimens examined in 2013 and 2014 in the Gharbiah province, Egypt were abstracted. Prevalence of hysterectomy was estimated and used for adjusting the incidence rate of uterine cancer in the Gharbiah population-based registry by excluding the hysterectomized women from the population at risk. Pre- and post- adjustment rates were compared and 95% confidence intervals (CIs) were calculated. Results: The prevalence of hysterectomy was estimated as 13.1 per 10,000 women, 95% CI (12.65-13.66). The prevalence of hysterectomy did not have a significant impact on uterine cancer incidence [pre-adjustment (2.78, 95% CI 2.58-3.00) and post-adjustment (2.79, 95% CI 2.58-3.00)]. Observing a significant effect of hysterectomy on underestimating the incidence of uterine cancer in this population required multiplying the observed prevalence by at least 110 times. Discussion: This study confirmed the previously documented low incidence of uterine cancer in this population of Egypt. The lack of evidence about the possible role of hysterectomy in lowering uterine cancer incidence justifies the need for additional research to identify the protective factors for uterine cancer in this population.


2018 ◽  
pp. 1-11 ◽  
Author(s):  
Solomon Tessema Memirie ◽  
Mahlet Kifle Habtemariam ◽  
Mathewos Asefa ◽  
Biniyam Tefera Deressa ◽  
Getamesay Abayneh ◽  
...  

Purpose Noncommunicable diseases, prominently cancer, have become the second leading cause of death in the adult population of Ethiopia. A population-based cancer registry has been used in Addis Ababa (the capital city) since 2011. Availability of up-to-date estimates on cancer incidence is important in guiding the national cancer control program in Ethiopia. Methods We obtained primary data on 8,539 patients from the Addis Ababa population-based cancer registry and supplemented by data on 1,648 cancer cases collected from six Ethiopian regions. We estimated the number of the commonest forms of cancer diagnosed among males and females in Ethiopia and computed crude and age-standardized incidence rates. Results For 2015 in Ethiopia, we estimated that 21,563 (95% CI, 17,416 to 25,660) and 42,722 (95% CI, 37,412 to 48,040) incident cancer cases were diagnosed in males and females, respectively. The most common adult cancers were: cancers of the breast and cervix, colorectal cancer, non-Hodgkin lymphoma, leukemia, and cancers of the prostate, thyroid, lung, stomach, and liver. Leukemia was the leading cancer diagnosis in the pediatric age group (age 0 to 14 years). Breast cancer was by far the commonest cancer, constituting 33% of the cancers in women and 23% of all cancers identified from the Addis Ababa cancer registry. It was also the commonest cancer in four of the six Ethiopian regions included in the analysis. Colorectal cancer and non-Hodgkin lymphoma were the commonest malignancies in men. Conclusion Cancer, and more prominently breast cancer, poses a substantial public health threat in Ethiopia. The fight against cancer calls for expansion of population-based registry sites to improve quantifying the cancer burden in Ethiopia and requires both increased investment and application of existing cancer control knowledge across all segments of the Ethiopian population.


Sign in / Sign up

Export Citation Format

Share Document